Instem plc Global R&D Organisation selects Centrus & SRS
May 29 2013 - 2:01AM
RNS Non-Regulatory
TIDMINS
Instem plc
29 May 2013
29 May 2013
Embargoed for 07:00
Instem plc
("Instem", the "Company" or the "Group")
Centrus and SRS selected by Global R&D Organisation
Integrated solution provides data aggregation, regulatory
submission and bioinformatics capabilities
Instem plc (AIM: INS.L), a leading provider of IT applications
to the global early development healthcare market, today announces
that a world leading healthcare company has purchased the complete
Centrus(TM) software suite and is the first to order Centrus SRS, a
comprehensive data integration and bioinformatics solution.
Centrus was launched in late 2010 and focuses on the areas of
enterprise information integration in early drug development,
management and reporting. The suite continues to build good
momentum, particularly the modules associated with the US Food and
Drug Administration sponsored Standard for the Exchange of
Non-clinical Data (SEND). It is therefore very pleasing to see this
Global R&D organisation purchasing the entire solution,
including Centrus submit(TM) to satisfy their own business
requirements while becoming compliant in meeting this important
FDA-endorsed standard.
The acquisition of BioWisdom in March 2011 accelerated the
development of the Centrus product suite and provided sophisticated
technologies to aggregate, analyse and extract knowledge from huge
volumes of disparate internal and external data, unlocking
considerable additional value from billions of dollars of prior
research investments. Centrus SRS is one of the latest examples of
how Instem is integrating key technology platforms to meet the
developing demand by clients for data-driven insights.
Using Centrus SRS, the client will be able to access, integrate
and query data being created from their own preclinical studies as
well as data received from their external study partners. This
cross-study search and browsing capability enables the client to
identify patterns and trends, generating important new knowledge
and actionable insight quickly and cost-effectively.
During 2012 Instem was recognised at the CDISC Interchange North
America meeting for its outstanding contributions toward the
completion of the SEND 3.0 Implementation Guide. More recently
Instem was delighted to have received the VOLTAGE Technology
Innovator Award for its submit-SEND solution at a ceremony in
Philadelphia in May 2013.
Phil Reason, CEO of Instem plc, further commented: "The SEND
standard is expected to be a catalyst for the uptake of Centrus, as
clients prioritise investments which satisfy new regulatory
requirements and support increased study outsourcing. We are
encouraged to see this client leverage its use of Centrus, and its
other processes, through our comprehensive Data Integration &
Bioinformatics technology platform, SRS. Our capabilities in this
area are very strong, and the technology reaches across all stages
of the process of drug discovery and development, not just our
Early Development core market.
"Instem's addressable market has been further expanded through
the acquisition of Logos Technologies, announced 13 May 2013. Entry
into the early clinical market also provides greater access to
early phase clinical data in both healthy and patient populations,
enhancing the potential of Instem's translational informatics
solutions."
For further information, please contact:
Instem plc +44 (0) 1785 825 600
Phil Reason, CEO
Nigel Goldsmith, CFO
N+1 Singer (Nominated Adviser &
Broker) +44 (0) 20 7496 3000
Aubrey Powell
Joe Stroud
Newgate Threadneedle +44 (0) 20 7653 9850
Fiona Conroy
Caroline Evans-Jones
About Instem plc
Instem is a leading supplier of IT applications to the early
development healthcare market delivering compelling solutions for
data collection, management and analysis across the R&D
continuum. Instem applications are used by customers worldwide,
meeting the rapidly expanding needs of life science and healthcare
organisations for data-driven decision making leading to safer,
more effective products.
Instem's portfolio of software solutions increases client
productivity by automating study-related processes while offering
the unique ability to generate new knowledge through the extraction
and harmonisation of actionable scientific information.
Instem supports its clients through full service offices in the
United States, United Kingdom and China with additional locations
in India and a full service distributor based in Japan.
To learn more about Instem solutions and its mission, please
visit www.instem.com or its investor centre
http://investors.instem.com/
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAQVLFLXEFBBBL
Instem (LSE:INS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Instem (LSE:INS)
Historical Stock Chart
From Jul 2023 to Jul 2024